SBC Medical Group (NASDAQ:SBC) Trading Down 3.4% - Here's What Happened

Key Points

• SBC Medical Group shares fell 3.4% to about $4.96, with trading volume down 44% from its average.
• Analyst views remain mixed: two analysts rate the stock Buy, one rates it Sell, and the overall consensus is Hold with an $8.50 target price.
• The company beat revenue expectations with $49.19 million in quarterly revenue but missed EPS estimates, reporting $0.10 versus the expected $0.12. Institutional investors own 60.82% of the stock.

SBC Medical Group Holdings Incorporated (NASDAQ:SBC - Get Free Report) dropped 3.4% during trading on Tuesday . The company traded as low as $4.82 and last traded at $4.9640. 60,345 shares were traded during trading, a decline of 44% from the average daily volume of 107,801 shares. The stock had previously closed at $5.14.

Analyst Upgrades and Downgrades

SBC has been the subject of several recent research reports. BTIG Research reiterated a "buy" rating and issued a $8.00 price target on shares of SBC Medical Group in a research report on Thursday, August 13th. Weiss Ratings reiterated a "sell (d+)" rating on shares of SBC Medical Group in a report on Wednesday, August 19th. Finally, Wall Street Zen raised SBC Medical Group from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, SBC Medical Group presently has a consensus rating of "Hold" and a consensus target price of $8.50.

SBC Medical Group Price Performance

The company has a market capitalization of $498.41 million, a P/E ratio of 10.31 and a beta of 0.63. The firm's fifty day moving average is $3.70 and its 200 day moving average is $3.54. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.27 and a current ratio of 3.31.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.02). SBC Medical Group had a return on equity of 18.47% and a net margin of 27.99%.The firm had revenue of $49.19 million during the quarter, compared to the consensus estimate of $45.37 million. As a group, analysts predict that SBC Medical Group Holdings Incorporated will post 0.44 earnings per share for the current fiscal year.

Institutional Trading of SBC Medical Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new position in SBC Medical Group during the 2nd quarter worth $446,000. Two Sigma Securities LLC purchased a new stake in shares of SBC Medical Group in the 2nd quarter worth $66,000. Bank of America Corp DE purchased a new stake in shares of SBC Medical Group in the 2nd quarter worth $35,000. BlackRock Inc. bought a new position in shares of SBC Medical Group during the 2nd quarter worth $2,846,000. Finally, Deutsche Bank AG purchased a new position in shares of SBC Medical Group during the second quarter valued at $58,000. Hedge funds and other institutional investors own 60.82% of the company's stock.

About SBC Medical Group

SBC Medical Group NASDAQ: SBC is a Japan-based medical services and management company focused primarily on the aesthetic medicine sector. Through its affiliated medical corporations and clinic network, the company supports the operation of facilities offering cosmetic surgery, cosmetic dermatology and related elective treatments.

The company provides a range of management and operational services to affiliated clinics, including branding and marketing, staff recruitment and training, purchasing, information technology, administrative support and business consulting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.